Ambit to Use $49M from Series D VC Round to Develop Kinase Inhibitor

Nov 14, 2007

NEW YORK (GenomeWeb News) — Ambit Biosciences has landed $49.3 million in a Series D round of private-equity financing from new and existing investors, the company said today.

Ambit plans to use the funding blast to push its pipeline of small molecule kinase inhibitors, including several drug candidates it has in clinical and pre-clinical development, the company said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Here We Are Again

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

In the Pink

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

All Tied Up in a Bow

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

This Week in PNAS

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.

Main menu